Disruption of FGF2-Heparin-FGFR1 Complex Formation by Antiangiogenic Small Molecule Found In Silico

Mahdiyeh sadat Mahdavi, Mohammad Ali Shokrgozar, Soroush Sardari, Mohammad Majidi, Mona Ghadam


Background: Basic fibroblast growth factor (FGF2), is one of the most potent proangiogenic proteins involved in tumor angiogenesis. Interaction of heparin with FGF2 and FGF2 receptor (FGFR1) form a ternary complex that is prerequisite for FGF2 proangiogenic activity. Therefore, this interaction can be an important target for inhibition of angiogenesis.

Methods: In this study, we performed screening studies by computer-aided techniques to find a small molecule interfering with this interaction. Based on ionic interactions, we found seventeen small molecules to have possiblity of angiogenic inhibition effect. According to important negative charge distances, benzene-1,2,4-tricarboxylic acids, known as Trimellitic acid (TMLA), was chosen. MTT viability test, Real Time PCR, Tube Formation assay and Flowcytometry technique were used to evaluate TMLA effect.

Results: Here we demonstrated viability of HUVECs was decreased after exposure to TMLA only at high concentrations. Real time PCR revealed that gene expression was dramatically decreased in comparison to negative control that indicates TMLA is an effective agent on reduction of CD31 expression. At half maximal inhibitory concentration (13mM), TMLA inhibited HUVEC tube formation process. Annexin V-FITC / PI flow cytometry technique revealed that TMLA inhibitory effect was via apoptosis.

Conclusion: The present work demonstrates that it is possible to extend the FGF2 inhibitors with much specificity based on ionic interactions strategy.


Angiogenesis; FGF2; Apoptosis; Small Molecule

Full Text:



Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. oncologist. 2004;volume 9(Supplement 1):2-10.

Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;volume 82(1):4-7.

Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opin Emerg Drugs. 2006;volume 11(4):635-50.

García-Fernández L, Halstenberg S, Unger RE, Aguilar MR, Kirkpatrick CJ, San Román J. Anti-angiogenic activity of heparin-like polysulfonated polymeric drugs in 3D human cell culture. Biomaterials. 2010;volume 31(31):7863-72.

Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol. 2001;volume 2(3):1-12.

Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol. 2000;volume 32(2):115-20.

Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological Roles of Fibroblast Growth Factor-2 1. Endocr Rev. 1997;volume 18(1):26-45.

Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science. 1993;volume 259(5103):1918-21.

Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;volume 21(285):1182-6.

Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;volume 1(1):27-30.

Casu B, Lindahl U. Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem. 2001;volume 57:159-206.

Bernfield M, Götte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;volume 68(1):729-77.

Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem. 1998;volume 67(1):609-52.

Fernández-Tornero C, Lozano RM, Redondo-Horcajo M, Gómez AM, López JC, Quesada E, et al. Leads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonate. J Biol Chem. 2003;volume 278(24):21774-81.

Lindahl U, Lidholt K, Spillmann D, Kjellén L. More to “heparin” than anticoagulation. Thromb Res. 1994;volume 75(1):1-32.

Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annual review of biochemistry. 1998;volume 67(1):609-52.

Klumpp S, Kriha D, Bechmann G, Maaßen A, Maier S, Pallast S, et al. Phosphorylation of the growth factors bFGF, NGF and BDNF: a prerequisite for their biological activity. Neurochem Int. 2006;volume 48(2):131-7.

Thompson LD, Pantoliano MW, Springer BA. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry. 1994;volume 33(13):3831-40.

Li L-Y, Safran M, Aviezer D, Boehlen P, Seddon AP, Yayon A. Diminished heparin binding of a basic fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry. 1994;volume 33(36):10999-1007.

Rose K, Gast RE, Seeger A, Krieglstein J, Klumpp S. ATP-dependent stabilization and protection of fibroblast growth factor 2. J Biotechnol. 2010;volume 145(1):54-9.

Friedl A, Chang Z, Tierney A, Rapraeger AC. Differential binding of fibroblast growth factor-2 and-7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues. Am J Pathol. 1997;volume 150(4):1443-55.

CHANG Z, MEYER K, RAPRAEGER AC, FRIEDL A. Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB Jl. 2000;volume 14(1):137-44.

Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;volume 6(3):743-50.

Rose K. Foscarnet reduces FGF2-induced proliferation of human umbilical vein endothelial cells and has antineoplastic activity against human anaplastic thyroid carcinoma cells. Biomed Pharmacother. 2013;volume 67(1):53-7.

Rose K, Finger I, Ferenz K. Interaction of clodronate with fibroblast growth factor 2 reduces FGF2-activity in endothelial cells. Biomed Pharmacother. 2011;volume 65(1):46-51.

Mikirova NA, Ichim TE, Riordan NH. Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med. 2008;volume 6(1):50.

Horak E, Klenk N, Leek R, LeJeune S, Smith K, Stuart N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992;volume 340(8828):1120-4.

Gagliardi A, Hadd H, Collins D. Inhibition of angiogenesis by suramin. Cancer Res. 1992;volume 52(18):5073-5.

Nguyen N, Lehr J, Pienta K. Pentosan inhibits angiogenesis in vitro and suppresses prostate tumor growth in vivo. Anticancer Res. 1992;volume 13(6A):2143-7.

Ziebart T, Pabst A, Klein MO, Kämmerer P, Gauss L, Brüllmann D, et al. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro. Clin Oral Investig. 2011;volume 15(1):105-11.

Schuksz M, Fuster MM, Brown JR, Crawford BE, Ditto DP, Lawrence R, et al. Surfen, a small molecule antagonist of heparan sulfate. PNAS. 2008;volume 105(35):13075-80.

Aviezer D, Cotton S, David M, Segev A, Khaselev N, Galili N, et al. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis. Cancer Res. 2000;volume 60(11):2973-80.

Colombo G, Margosio B, Ragona L, Neves M, Bonifacio S, Annis DS, et al. Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. J Biol Chem. 2010;volume 285(12):8733-42.

Foglieni C, Pagano K, Lessi M, Bugatti A, Moroni E, Pinessi D, et al. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Sci Rep. 2016;volume 6:23432.

Manetti F, Corelli F, Botta M. Fibroblast growth factors and their inhibitors. Curr Pharm Des. 2000;volume 6(18):1897-924.

Ronca R, Giacomini A, Di Salle E, Coltrini D, Pagano K, Ragona L, et al. Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. Cancer Cell. 2015;volume 28(2):225-39.

DOI: http://dx.doi.org/10.31557/APJCB.2017.2.2.27


  • There are currently no refbacks.

Copyright (c) 2017 Asian Pacific Journal of Cancer Biology

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.





Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention